Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Cardiac biomarkers for risk stratification based on clinical outcomes after ischemic stroke or transient ischemic attack.

Created on 15 Nov 2026

Authors

Tomma S Gloystein, Märit Jensen, Susanne Lezius, Bastian Cheng, Robert Schulz, Elke Oetjen, Tim Magnus, Götz Thomalla, Edzard Schwedhelm, Tanja Zeller, Chi-Un Choe

Published in

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. Pages 108787. Nov 14, 2026. Epub Nov 14, 2026.

Abstract

Following ischemic stroke or transient ischemic attack, patients remain at increased risk of adverse neurological and cardiovascular events. Cardiac biomarkers reflecting distinct pathomechanisms may improve risk stratification. We evaluated associations of N-terminal pro-B-type natriuretic peptide (NT-proBNP), midregional pro-atrial natriuretic peptide (MR-proANP), and high-sensitivity troponin I (hsTnI) with stroke severity and adverse events and explored a two-step biomarker approach to identify high-risk patients.
In the prospective, single-center bioMARKers in STROKE (MARK-STROKE) cohort (University Medical Center Hamburg Eppendorf, Germany), MR-proANP, NT-proBNP, and hsTnI were measured in 374 patients with ischemic stroke or transient ischemic attack. Biomarker concentrations were log2-transformed, with effect estimates expressed per doubling. Follow-up was available for 273 patients. Stroke severity was assessed by the National Institutes of Health Stroke Scale (NIHSS). Adverse events (death, myocardial infarction, recurrent stroke, rehospitalization) were recorded during a median of 278 days (interquartile range 184-367). Associations were investigated using age- and sex-adjusted linear, logistic, and Cox regression models. To explore whether combining biomarkers provides additional prognostic information, patients were stratified by the MR-proANP median, with those above the median further stratified by the subgroup-specific hsTnI median.
Higher MR-proANP concentrations were associated with higher NIHSS scores on admission (adjusted β 0.64; 95% CI 0.25-1.02; p=0.001) and an increased risk of adverse events (adjusted HR 1.50; 95% CI 1.21-1.87; p<0.001). NT-proBNP showed similar but weaker associations, whereas hsTnI was not significantly associated with adverse events. Among patients with MR-proANP concentrations above the median, those with hsTnI concentrations above the subgroup-specific hsTnI median had the lowest event-free survival in Kaplan-Meier analysis (log-rank p=0.008).
Cardiac biomarkers, particularly MR-proANP, provide prognostic information after ischemic stroke or transient ischemic attack. A two-step algorithm using MR-proANP for initial classification and hsTnI for refinement may identify patients at increased risk and requires prospective validation.

PMID:
43033880
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement